Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Amer M. Zeidan, MBBS, MHS, Victoria Wang, Jerald P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD, Elad Sharon, MD MPH, Steven D. Gore, MD, Selina M. Luger, MD FRCPC, Mark Litzow, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137734

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Amer M. Zeidan, MBBS, MHS, Prajwal Boddu, MD, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139752

Published: 2020

Journal Articles

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Prajwal C Boddu, MBBS, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-139668

Published: 2020

Journal Articles

Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia

Jacob Higgins, PhD, Fang Yin Lo, PhD, Michael J. Hipp, MS, Charles C. Valentine, MS, Lindsey N. Williams, PhD, Amanda R. Leonti, MS, Rhonda E. Ries, MA, Jerald P. Radich, MD, Soheil Meshinchi, MDPhD, Benjamin J. Huang, MD, Jesse J. Salk, MD PhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-143062

Published: 2020

Journal Articles

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134211

Published: 2020

Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 2932.

https://doi.org/10.1182/blood-2019-129393

Published: 2019

Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Blood (2019) 134 (Supplement_1): 2691.

https://doi.org/10.1182/blood-2019-124529

Published: 2019

Journal Articles

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Blood (2019) 134 (Supplement_1): 2578.

https://doi.org/10.1182/blood-2019-125131

Published: 2019

Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker

Blood (2019) 134 (Supplement_1): 665.

https://doi.org/10.1182/blood-2019-124716

Published: 2019

Journal Articles

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Masumi Ueda, MD, Lan Beppu, Judy Campbell, RN, Mary E. D. Flowers, MD, Jerald P. Radich, MD, Rainer Storb, MD

Blood (2019) 134 (Supplement_1): 702.

https://doi.org/10.1182/blood-2019-126979

Published: 2019

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Ehab L. Atallah, MD, Vamsi Kota, MBBS, Islam Sadek, Andrea Damon, PhD, Ji-May Jen, PharmD, Berna Cakmak, BPharm, Joshua Landy, MD FRCPC, Sharon Vorona, MBBS, Jerald P. Radich, MD

Blood (2019) 134 (Supplement_1): 5842.

https://doi.org/10.1182/blood-2019-124809

Published: 2019

Journal Articles

Characterization of Clonal Dynamics after Hematopoietic Cell Transplantation Using Ultra-Sensitive Duplex Sequencing

Jacob Higgins, PhD, Gabriel Pratt, PhD, Charles C. Valentine, MS, Lindsey N. Williams, PhD, Masumi Ueda, MD, Rainer Storb, MD, Jerald P. Radich, MD, Jesse J. Salk, MD PhD

Blood (2019) 134 (Supplement_1): 2483.

https://doi.org/10.1182/blood-2019-122490

Published: 2019

Journal Articles

Duplex Sequencing Accurately Detects Variants below 1/100,000 in Genes Recurrently Mutated in Acute Myeloid Leukemia

Jacob E. Higgins, PhD, Lindsey N. Williams, PhD, Sarah A Buckley, MD, Christopher S. Hourigan, DPhil FACP FRCP, Jerald P. Radich, MD, Jesse J. Salk, MD PhD

Blood (2018) 132 (Supplement 1): 2769.

https://doi.org/10.1182/blood-2018-99-115071

Published: 2018

Journal Articles

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

Ryan D. Cassaday, MD, Lorinda A. Soma, MD, Olga Sala-Torra, MD, Philip A. Stevenson, MS, Mary-Elizabeth M. Percival, MD, Vivian G. Oehler, MD, Andrei R. Shustov, MD, Pamela S. Becker, MD, Anna B. Halpern, MD, Kelsey-Leigh Garcia, Christen N. Heye, ARNP, Jerald P. Radich, MD, Elihu H. Estey, MD

Blood (2018) 132 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2018-99-110661

Published: 2018

Journal Articles

Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Nicholas J Short, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Marina Y. Konopleva, MD PhD, Ghayas C. Issa, MD, Rashmi Kanagal-Shamanna, MD, Steven M. Kornblau, MD, Guillermo Garcia-Manero, MD, Victor Rivera, PhD, Rebecca E. Garris, MSc, Jesse Salk, PhD, Justin Prichard, PhD, Jerald P. Radich, MD, Elias J. Jabbour, MD

Blood (2018) 132 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2018-99-115369

Published: 2018

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Markus Pfirrmann, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD PhD, Francis J. Giles, MD MB, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Giuseppe Saglio, MD PhD, Weiping Deng, Darshan Dalal, MPH, MD PhD, Susanne Saussele, MD

Blood (2017) 130 (Supplement 1): 1601.

https://doi.org/10.1182/blood.V130.Suppl_1.1601.1601

Published: 2017

NARROW

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Characterization of Clonal Dynamics after Hematopoietic Cell Transplantation Using Ultra-Sensitive Duplex Sequencing

Duplex Sequencing Accurately Detects Variants below 1/100,000 in Genes Recurrently Mutated in Acute Myeloid Leukemia

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only